Conference Abstract

Title Average Ratingsort ascending
A phase II, single arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with unresectable m 100.00%
A phase II, single arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with metastatic bladder cancer. 100.00%
A phase II, single-arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with advanced non-s 100.00%
A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gal 100.00%
Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) ...... 95.00%
Metronomic schedule of temozolomide with conventional dose of cisplatin in metastatic melanoma. Sub-category: Melanoma Categor 90.00%
A randomized trial of personalized peptide vaccine (PPV) plus low-dose estramustine (EMP) versus full-dose EMP in patients ..... 90.00%
Cellular immune suppression in cancer patients and its implication for dendritic cell therapy. Sub-category: Cell-Based Therapy 90.00%
Dendritic cell-based vaccination in combination with gemcitabine/S-1 in patients with advanced pancreatic cancer. Sub-category: 90.00%
Hyperthermia and radiation therapy for locally advanced or recurrent breast cancer. 90.00%
A phase II, single-arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with advanced esoph 90.00%
Adjuvant vaccination with melanoma antigen pulsed dendritic cells (DCs) in stage III melanoma patients. 85.00%
Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of local.. 80.00%
Activity of a multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen in metastatic renal cell carcinoma (m 80.00%
A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma 80.00%
Evaluation of the treatment of peritoneal carcinomatosis of colorectal cancer (CRC) with complete cytoreduction and hyperthe.... 80.00%
Synergistic activity of PHY906 with capecitabine in pancreatic carcinoma. 80.00%
Bevacizumab for recurrent ependymoma. 80.00%
Treatment of locally advanced pancreatic cancer with concurrent uftoral and radiotherapy. Results from 64 patients treated from 80.00%
Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGN 80.00%
Therapeutic vaccination with an autologous TriMix-Dendritic cell vaccine combined with sequential interferon alfa-2b in ........ 80.00%
A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. 80.00%
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients .... 80.00%
Dendritic cell vaccination in melanoma patients: Update and subgroup analysis of clinical response to post-vaccine treatment. 80.00%
Impressive survival data with semimetronomic oral chemotherapy with old agents in heavily treated metastatic breast cancer..... 75.00%
Effect of metronomic use of zoledronic acid (ZOL) on antitumor and antiosteoclastic effects in breast cancer patients with bone 70.00%
Sorafenib and radiation: A promising combination in colorectal and pancreas cancer 70.00%
Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors. 70.00%
Antitumor activity of patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells: In vitro results and cli 70.00%
A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination.............. 70.00%
Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma 70.00%
Phase II trial of pharmacodynamically (PDally)-guided optimal biologic dose titration (OBDT) of sorafenib (S) in combination wit 70.00%
A phase II trial of an adenovirus/PSA vaccine for prostate cancer. 70.00%
Randomized phase II trial of capecitabine versus capecitabine, low molecular weight heparin, and prednisone in refractory....... 70.00%
Hypoxia-inducible factor-1alpha modulation in combination with anti-angiogenic therapy. 60.00%
Final results of a pharmacokinetic (PK) and pharmacodynamic (PD) phase I trial of ARQ 197 incorporating dynamic contrast........ 60.00%
Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer...... 60.00%
SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel 60.00%
Therapeutic vaccination against advanced pancreatic cancer by autologous dendritic cells pulsed with a MUC1 peptide: Preclinic.. 60.00%
Correlation of immune responses and survival in a phase II study of belagenpumatucel-L in non-small cell lung cancer. 60.00%
CECs, CEPs and CTCs for prediction of response in patients with advanced breast cancer (ABC) receiving metronomic vinorelbine. 60.00%
A phase I trial of tumor-associated antigen-pulsed dendritic cell immunotherapy for patients with brain stem glioma and glio.... 60.00%
Tissue factor, angiogenesis and thrombosis in pancreatic cancer. 60.00%
Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer. 60.00%
Preclinical antitumor and antiangiogenic activity of a metronomic schedule of cisplatin against human transitional cell carcinom 50.00%
A novel metronomic schedule of oral vinorelbine for the treatment of metastatic breast cancer in elderly patients............... 50.00%
An RF hyperthermia electrode which generates no edge effect. 50.00%
Evaluation of recombinant bacillus Calmette-Guerin expressing pertussis toxin in bladder cancer. 50.00%
A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC) 50.00%
MET in small cell lung carcinoma (SCLC): Effects of a MET inhibitor in SCLC cell lines and prognostic role of MET status in pati 50.00%
Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). 50.00%
Phase I adjuvant trial of multi-epitope p53 vaccine for patients with squamous cell carcinoma of the head and neck (SCCHN): A pr 45.00%
Phase I trial of capecitabine (Cap) and gemcitabine (G) with concurrent radical radiotherapy in locally advanced pancreatic ca.. 40.00%
Ifosfamide, carboplatin, and etoposide (ICE) in combination with regional hyperthermia (RHT) in chemotherapy-pretreated non..... 40.00%
A phase I study of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. 40.00%
Control of cancer-associated inflammation and survival: Results from a prospective randomized phase II trial in gastric cancer. 40.00%
Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab.... 40.00%
Hepatocyte growth factor as inducer of gefitinib resistance in non-small cell lung cancer harboring EGFR activating mutations. 40.00%
Serum cytokines in pancreatic cancer: Correlation with outcome 40.00%
Correlation between prior therapeutic dendritic cell vaccination and the outcome of patients with metastatic melanoma treated... 30.00%
Outpatient administration of high-dose methotrexate for osteosarcoma treatment in Brazil. 30.00%
Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced... 30.00%
Pharmacology and safety factors affecting use of flat (rather than weight-based) dosing of tesetaxel, an orally administered.... 30.00%
Oral metronomic chemotherapy using cyclophosphamide in metastatic patients (pts) after standard treatment: Results of a randomiz 25.00%
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. 0.00%